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Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly
in patients with tumours harbouring activating KIT mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a
consecutive series of patients with high-risk tumours (n¼23) was compared with historic controls (n¼48) who were treated with
surgery alone. The mean follow-up period was over 3 years in both groups. Only 1 out of 23 patients (4%) in the adjuvant treatment
group developed recurrent disease compared to 32 out of 48 patients (67%) in the control group. This preliminary study indicates
that 1 year of adjuvant treatment with imatinib dramatically improves recurrence-free survival. Confirmation of these findings awaits
the results of ongoing randomised studies.
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The survival of patients with metastatic and inoperable malignant
gastrointestinal stromal tumours (GIST), particularly those whose
tumours have KIT exon 11 mutations, has improved dramatically
since the introduction of imatinib mesylate into treatment
protocols (Verweij et al, 2004). The role of adjuvant imatinib
treatment in GIST, however, is unclear and is currently being
investigated in ongoing trials. Four such studies, including patients
have undergone radical (R0) surgery, are currently being
conducted with different inclusion criteria in terms of malignant
potential according to the consensus grading system of Fletcher
et al (2002). ACOSOG Z9000 addresses treatment with imatinib
(400mgday
 1 p.o.(orally)) for 1 year in patients with high-risk
GIST with no control arm, while ACOSOG Z9001 compares
imatinib treatment with placebo in patients with tumours X3cm
(low, intermediate, and high-risk tumours). EORTC 62024 is
designed for patients with intermediate- and high-risk GIST
treated with imatinib (400mgday
 1 p.o.(orally)) vs placebo for 2
years. Finally, SSG XVIII includes high-risk GIST treated with
imatinib (400mgday
 1 p.o.(orally)) for either 1 or 3 years.
The purpose of this study was to report our experience with
adjuvant imatinib, while awaiting the results of ongoing multi-
centre trials. Our study consists of a single-centre, consecutive
pilot series of 23 patients with high-risk GIST who have been
treated with adjuvant imatinib (400mgday
 1) for 1 year after R0
resection. These cases are compared with historical controls from a
previous population-based series (Nilsson et al, 2005; Bumming
et al, 2006) with matched risk scores with respect to tumour size
and maximal proliferative activity with Ki67 antibodies.
MATERIALS AND METHODS
The pilot adjuvant imatinib study group consisted of 23
consecutive patients (11 women and 12 men; mean age 56 years,
range 21–82 years) with high-risk GIST diagnosed between
February 2001 and June 2005. The mean tumour size was 9.4cm
(s.d.¼7.7, range 2–35cm), and the mean Ki67 max% (maximum
percentage of cells positive with Ki67 immunostains) was 7.0 (s.d.
5.0, range 2–10%). These patients received adjuvant imatinib
(400mgday
 1 p.o.(orally)) for 12 months after R0 resection. The
mean follow-up after onset of imatinib treatment was 40 months
(s.d.¼14, range 18–62 months). Mutational analyses of KIT exons
9, 11, 13, and 17 and PDGFRA exons 12 and 18 were performed
with dHPLC and bidirectional direct sequencing in both patient
groups (Andersson et al, 2006).
The majority of patients (19 out of 23, 83%) receiving adjuvant
imatinib had tumours with mutations in KIT or PDGFRA.
Seventeen patients had tumours with KIT exon 11 mutations
(eight deletions, five missense mutations, and four duplications).
One patient had a GIST with duplication in KIT exon 9 and one
patient’s tumour had deletion in PDGFRA exon 18. Four patients
had tumours that lacked KIT and PDGFRA mutations.
There were 48 matched (with regard to tumour size and Ki67
max %) historical controls of high-risk GIST with R0 resections,
including 25 women and 23 men with a mean age of 67 years (s.d.
13, range 25–87 years). Mean tumour size was 12.3cm (s.d.¼7,
range 3.5–33cm), and mean Ki67 max% was 11.7 (s.d.¼11.8,
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srange 0.5–40%) These patients had a mean follow-up of 36 months
(s.d.¼41, range 2–151 months). Twenty-nine patients had
tumours with KIT exon 11 mutations (20 deletions, six missense
mutations, three duplications), one tumour had a missense
mutation in PDGFRA exon 12 and 18 patients had tumours that
were wild type (WT) in KIT and PDGFRA (Table 1).
Statistics
Continuous data from the different groups were compared using
the non-parametric Mann–Whitney test. Categorical data from
different groups were compared using Fisher’s exact test.
Recurrence-free survival (i.e. proportion of patients alive and
without recurrent disease) was recorded from the time of initial
diagnosis to the time of first recurrence or tumour-related death.
Disease-free survival was calculated using the Kaplan–Meier
method. Differences between groups were compared by the log–
rank test. All statistical tests were two-sided.P o0.050 was
considered statistically significant.
RESULTS AND DISCUSSION
Only high-risk GIST were included in this pilot adjuvant imatinib
study, in contrast to ongoing adjuvant trials that also include
intermediate-risk and even low-risk GIST. The selection of patients
with high-risk GIST was based on follow-up data from our
previously published population-based study of 233 GIST patients
(Nilsson et al, 2005). Given the high prognostic impact of both
larger tumour size and higher proliferative index (Ki67 immuno-
labelling), we selected a historical control group that matched the
adjuvant treatment group with respect to these parameters.
The estimated recurrence-free survivals for the adjuvant
treatment and control group are presented in Figure 1. Only 1
out of 23 (4%) patients developed recurrent disease in the
treatment group in contrast to 32 out of 48 (67%) in the control
group. In the current series, as well as in our large population-
based series (Nilsson et al, 2005), the vast majority of recurrences
in high-risk GIST are within 2 years of diagnosis. Notably, there
was no recurrent disease in the treatment group during the first
2 years after diagnosis.
The only recurrence in the treatment group was in a 10-year-old
girl with a small intestinal GIST; after five resections for
recurrences over a 12-year period (the last being a hemi-
hepatectomy for liver metastasis), she received adjuvant imatinib
for 12 months. Twenty-two months after termination of imatinib
treatment, a small lung metastasis was detected and removed.
There is a distinct, rare subgroup of malignant GIST associated
with a protracted clinical course despite multiple distant
metastases over a long period of time. These have a distinct
predilection for young females and have been shown to lack KIT
and PDGFRA mutations (Persson et al, 1992; Miettinen et al, 2005).
Interestingly, this girl’s GIST also lacked KIT and PDGFRA
mutations. These findings are consistent with previous reports
that GIST with KIT exon 11 mutations have the highest response
rate to palliative treatment with imatinib.
We have recently shown that KIT mutation status is an
independent prognostic factor in GIST in addition to tumour size
and proliferative index (Andersson et al, 2006). The overall
mutation frequency was somewhat higher in the adjuvant
treatment group (19 out of 23, 83%) compared to the control
group (30 out of 48, 63%). The reasons for this are probably
technical (older paraffin-embedded material in the control series
and some analyses performed on fresh frozen material in the
adjuvant treatment group) (Andersson et al, 2006; Kindblom et al,
2006). However, the frequency of KIT exon 11 deletions, which
have been found to be associated with a more aggressive clinical
course (Andersson et al, 2006), was similar in the two groups, with
8 out of 17 KIT mutations in the adjuvant treatment group and 20
out of 29 KIT mutations in the control group were deletions.
In summary, our study shows that 1 year of imatinib
(400mgday
 1 p.o.(orally)) treatment after R0 resections for
high-grade GIST dramatically reduces the risk of recurrent disease.
These results await confirmation with ongoing prospective
adjuvant treatment trials.
Table 1 Clinical data and tumour characteristics
Receptor tyrosine kinase mutations
Group
Number of
patients
Mean
tumour
size (cm) Ki67 max%
Mitotic
rate
(/50hpf)
KIT
ex 11
KIT
ex 9
PDGFRA
ex 18
PDGFRA
ex 12 WT
Mean
follow-up
(months)
Adjuvant
imatinib
23 9.4 7.0 6.2 del: 8 dupl: 1 del: 1 0 4 40
F: 11 s.d. 7.7 s.d. 5.0 s.d. 2.6 miss: 5 s.d. 14
M: 12 range 2–35 range 2–10 range 2–10 dupl: 4 range 18–62
Historic
controls
48 12.3 11.7 6.8 del: 20 0 0 miss: 1 18 36
F: 25 s.d. 7 s.d. 11.8 s.d. 3.3 miss: 6 s.d. 41
M: 23 range 3.5–33 range 0.5–40 range 2–10 dupl: 3 range 2–151
Abbreviations: del¼deletion; dupl¼duplication; ex¼exon; F¼female; hpf¼high power fields; M¼male; miss¼missense mutation; PDGFRA¼platelet-derived growth factor
receptor a;W T¼wild type (in KIT and PDGFRA).
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Figure 1 Kaplan–Meier estimates of recurrence-free survival in patients
with high-risk GIST. Historical controls (black) were only treated with R0
resection (mean follow-up 36 months, range 2–151 months), while the
consecutive series of patients (mean follow-up 40 months, range 18–62
months) had adjuvant imatinib (400mgday
 1) for 1 year after radical
surgery (red). In the latter group only one patient has developed
recurrence.
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